Galera Therapeutics is a company developing and commercializing cancer therapeutics, with a focus on radiotherapy. Their lead product candidate, avasopasem manganese, has completed Phase III clinical trial for the treatment of radiotherapy-induced severe oral mucositis in patients with head and neck cancer, and is also being tested for the treatment of radiotherapy-induced esophagitis and in patients with HNC undergoing standard-of-care radiotherapy. Galera Therapeutics is also involved in developing GC4711 in clinical trials for non-small cell lung cancer and locally advanced pancreatic cancer.